India’s anti-obesity drug market has experienced a staggering sixfold increase over the past five years, driven by surging demand among urban professionals and the growing prevalence of obesity and diabetes. Originally developed to manage diabetes, drugs like semaglutide (marketed as Rybelsus and Wegovy) and tirzepatide (sold as Mounjaro) are now being hailed as revolutionary weight-loss solutions. These GLP-1 drugs, which mimic a natural hormone regulating hunger, slow digestion and act on the brain’s appetite centers, helping users feel full longer. However, their rapid adoption has sparked concerns about misuse, lack of medical supervision, and the risks of side effects such as nausea, gallstones, and muscle loss.